白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00874 白云山

交易中 11-05 14:26:42

18.620

+0.160

+0.87%

最高18.680	最低18.400	成交量128.60万
今开18.400	昨收18.460	日振幅1.52%
总市值302.72亿	流通市值40.96亿	总股本16.26亿
成交额2,389万	换手率0.58%	流通股本2.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"白云山","latestPrice":18.62,"timestamp":1730787967201,"preClose":18.46,"halted":0,"volume":1286000,"delay":0,"floatShares":220000000,"shares":1625790949,"eps":2.7284138,"marketStatus":"交易中","marketStatusCode":2,"change":0.16,"latestTime":"11-05 14:26:42","open":18.4,"high":18.68,"low":18.4,"amount":23893432,"amplitude":0.015168,"askPrice":18.64,"askSize":20000,"bidPrice":18.62,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":2.302980015952609,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1730794200000},"adr":0,"listingDate":878140800000,"adjPreClose":18.46,"dividendRate":0.067456,"openAndCloseTimeList":[[1730770200000,1730779200000],[1730782800000,1730793600000]],"volumeRatio":0.911584,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":28.7,"timestamp":1730787997000,"preClose":28.36,"halted":0,"volume":10898578,"delay":0,"premium":"-40.68"}},"requestUrl":"/m/hq/s/00874/tweets","defaultTab":"tweets","newsList":[{"id":"2480300428","title":"白云山：分公司两款药品通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300428","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480300428?lang=zh_cn&edition=full","pubTime":"2024-11-01 19:50","pubTimestamp":1730461846,"startTime":"0","endTime":"0","summary":"每经AI快讯，白云山(600332)11月1日晚间公告，分公司白云山制药总厂收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克洛干混悬剂和注射用头孢呋辛钠已通过仿制药质量和疗效一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411013226790549.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411013226790549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00874","BK1191","BK1197","BK1515","BK1606","BK1521"],"gpt_icon":0},{"id":"2480004280","title":"白云山获批两款药品一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480004280","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480004280?lang=zh_cn&edition=full","pubTime":"2024-11-01 19:42","pubTimestamp":1730461374,"startTime":"0","endTime":"0","summary":"财中社11月1日电白云山（600332/00874）发布公告称，其分公司白云山制药总厂近日收到国家药品监督管理局核准，头孢克洛干混悬剂和注射用头孢呋辛钠已通过仿制药质量和疗效一致性评价。这一评估的通过将有助于提升这两款药品的市场竞争力。头孢克洛干混悬剂于2011年3月上市，2023年度销售收入为147万元，研发投入约525万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411013226786512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","00874","BK1606","BK1191","BK1515","BK1521"],"gpt_icon":0},{"id":"2480005490","title":"白云山(00874)分公司药品通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480005490","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480005490?lang=zh_cn&edition=full","pubTime":"2024-11-01 18:57","pubTimestamp":1730458679,"startTime":"0","endTime":"0","summary":"白云山(00874)发布公告，近日，公司分公司广州白云山医药集团股份有限公司白云山...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00874","BK0096","BK0028","BK0070","BK1521","BK0012","BK0175","BK0239","BK0188","BK0196","BK1515","BK0183","BK1606","600332","BK1197","BK1191","BK0097"],"gpt_icon":0},{"id":"2480058080","title":"白云山最新公告：头孢克洛干混悬剂和注射用头孢呋辛钠已通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480058080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480058080?lang=zh_cn&edition=full","pubTime":"2024-11-01 18:50","pubTimestamp":1730458231,"startTime":"0","endTime":"0","summary":"白云山公告，分公司白云山制药总厂收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克洛干混悬剂和注射用头孢呋辛钠已通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100038930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600332","BK0239","BK0175","BK0183","BK0188","BK0097","BK1197","00874","BK1515","BK1521","BK0196","BK1191","BK0070","BK1606","BK0028","BK0096"],"gpt_icon":0},{"id":"2480300321","title":"白云山(600332.SH)：头孢克洛干混悬剂和注射用头孢呋辛钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300321","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480300321?lang=zh_cn&edition=full","pubTime":"2024-11-01 18:45","pubTimestamp":1730457932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)发布公告，公司分公司广州白云山医药集团股份有限公司白云山制药总厂(简称“白云山制药总厂”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，头孢克洛干混悬剂和注射用头孢呋辛钠已通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0097","BK1515","BK1521","600332","BK0183","BK0070","BK0196","BK1191","BK0188","BK1197","00874","BK1606","BK0239","BK0028","BK0175","BK0096"],"gpt_icon":0},{"id":"2480758079","title":"白云山11月01日获主力加仓529万元 环比增加356.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480758079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480758079?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:16","pubTimestamp":1730448986,"startTime":"0","endTime":"0","summary":"11月01日, 白云山股价涨0.33%，报收18.34元，成交金额5601万元，换手率1.39%，振幅1.97%，量比1.74。白云山今日主力资金净流入529万元，上一交易日主力净流入116万元，今日环比增加356.03%。该股近5个交易日下跌3.88%，主力资金累计净流入461万元；近20日主力资金累计净流入1778万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101161706ab90fba4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101161706ab90fba4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1197","BK1521","BK1606","00874","BK1515"],"gpt_icon":0},{"id":"2480970051","title":"白云山金戈：口碑销量双增 助推健康事业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2480970051","media":"广州日报新花城","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480970051?lang=zh_cn&edition=full","pubTime":"2024-11-01 01:14","pubTimestamp":1730394888,"startTime":"0","endTime":"0","summary":"近期，广东省科技大会颁发2023年度省科学技术奖，由广州市科学技术局提名，白云山制药总厂牵头的项目“男性健康治疗药物研发关键技术突破与产业化创新升级”荣获2023年度广东省科技进步奖二等奖；刚刚过去的2024年中国男性健康日主题是“人口发展高质量，男性健康全周期”；眼下，“双11”脚步渐近，男性健康药品被认为将迎来再一次的销售放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411013225195928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00874","BK1191","BK1197","BK1515","BK1606","BK1521"],"gpt_icon":0},{"id":"2479756086","title":"挪威中央银行减持白云山(00874)40.4万股 每股作价约18.77港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479756086","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479756086?lang=zh_cn&edition=full","pubTime":"2024-10-31 19:32","pubTimestamp":1730374320,"startTime":"0","endTime":"0","summary":"联交所最新资料显示，10月29日，挪威中央银行减持白云山(00874)40.4万股，每股作价18.7675港元，总金额约为758.21万港元。减持后最新持股数目约为2185.1万股，最新持股比例为9.94%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-10-31/doc-incunauc9617067.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-10-31/doc-incunauc9617067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0175","BK0028","BK0183","BK0096","BK1521","BK0196","BK1606","BK0070","600332","BK0239","BK1191","00874","BK1197","BK0012","BK0188","BK0097","BK1515"],"gpt_icon":0},{"id":"2479728164","title":"Norges Bank减持白云山(00874)79.4万股 每股作价约19.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479728164","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479728164?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:21","pubTimestamp":1730197299,"startTime":"0","endTime":"0","summary":"10月23日，Norges Bank减持白云山(00874)79.4万股，每股作价19.2828港元，总金额约为1531.05万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20241029/20241029182146_78837.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241029/20241029182146_78837.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0175","BK0028","BK0183","BK0096","BK1521","BK0196","BK1606","BK0070","600332","BK0239","BK1191","00874","BK1197","BK0012","BK0188","BK0097","BK1515"],"gpt_icon":0},{"id":"2479147626","title":"白云山：子公司《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2479147626","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479147626?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:00","pubTimestamp":1730196043,"startTime":"0","endTime":"0","summary":"格隆汇10月29日丨白云山公告，近日，广州白云山医药集团股份有限公司子公司广州白云山奇星药业有限公司收到广东省药品监督管理局核准签发的《药品生产许可证》，同意在奇星药业委托广州白云山中一药业有限公司生产金丹丸的基础上，增加在生产车间“制造二部二区”包装。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029180100ab7e69ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029180100ab7e69ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00874","BK1521","BK1515","BK1606","BK1197","BK1191"],"gpt_icon":0},{"id":"2479475484","title":"白云山(00874)子公司《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2479475484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479475484?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:58","pubTimestamp":1730195887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，公司子公司广州白云山奇星药业有限公司(以下简称“奇星药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意在奇星药业委托广州白云山中一药业有限公司(以下简称“中一药业”)生产金丹丸的基础上，增加在生产车间“制造二部二区”包装。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","600332","BK0239","BK0175","BK0183","BK0188","BK0097","BK1197","00874","BK1515","BK1521","BK0196","BK1191","BK0070","BK1606","BK0028","BK0096"],"gpt_icon":0},{"id":"2479445750","title":"白云山全资子公司广药总院获GLP认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2479445750","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479445750?lang=zh_cn&edition=full","pubTime":"2024-10-29 13:43","pubTimestamp":1730180638,"startTime":"0","endTime":"0","summary":"财中社10月29日电白云山（600332/00874）发布公告称，其全资子公司广州医药研究总院有限公司（广药总院）近日顺利通过国家药品监督管理局的GLP定期检查，并获得新的《药物GLP认证证书》。该证书包括9项认证资质，有效期至2029年10月14日。此次认证符合《中华人民共和国药品管理法》及相关管理办法的要求，表明广药总院在药物非临床安全性评价研究方面具备了较强的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410293221133444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","GLP","BK1191","BK4144","BK1521","BK4590","BK1515","BK1606","00874"],"gpt_icon":0},{"id":"2478172863","title":"白云山：注射用头孢唑肟钠、缩宫素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2478172863","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478172863?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:37","pubTimestamp":1730108228,"startTime":"0","endTime":"0","summary":"格隆汇10月28日丨白云山(00874.HK)发布公告，近日，公司分公司广州白云山医药集团股份有限公司白云山制药总厂(简称“白云山制药总厂”)、全资子公司广州白云山明兴制药有限公司(简称“明兴药业”)分别收到国家药品监督管理局签发的《药品补充申请批准通知书》，注射用头孢唑肟钠、缩宫素注射液已通过仿制药质量和疗效一致性评价。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028174228ab7b2cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028174228ab7b2cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1197","BK1521","BK1606","00874","BK1515"],"gpt_icon":0},{"id":"2478317115","title":"白云山(00874)：注射用头孢唑肟钠和缩宫素注射液通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2478317115","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478317115?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:23","pubTimestamp":1730107427,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，该公司分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称“白云山制药总厂”)、全资子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)分别收到国家药品监督管理局签发的《药品补充申请批准通知书》，注射用头孢唑肟钠、缩宫素注射液已通过仿制药质量和疗效一致性评价。本次注射用头孢唑肟钠和缩宫素注射液通过仿制药质量和疗效一致性评价，有利于提升上述药品的市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","600332","BK0239","BK0175","BK0183","BK0188","BK0097","BK1197","00874","BK1515","BK1521","BK0196","BK1191","BK0070","BK1606","BK0028","BK0096"],"gpt_icon":0},{"id":"2478171594","title":"白云山(00874)：广药总院通过GLP定期检查并获得《药物GLP认证证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2478171594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478171594?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:22","pubTimestamp":1730107360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“公司”)全资子公司广州医药研究总院有限公司(以下简称“广药总院”)收到国家药品监督管理局颁发新的《药物GLP认证证书》。广药总院为公司主要研发平台之一，其药物非临床评价研究中心在2023年7月新版《药物非临床评价研究质量规范认证管理办法》实施后，具备了9项药物非临床安全性评价项目认证资质能力，有利于广药总院承接自主研发项目和对外承接药物非临床安全性评价业务，提升公司药物创新研发综合实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GLP","BK0028","BK1521","BK4590","BK0188","BK1197","BK0012","BK0070","BK0196","BK0183","BK0175","BK1606","BK0097","BK0096","BK1191","BK0239","00874","BK1515","BK4144","600332"],"gpt_icon":0},{"id":"2478179778","title":"白云山最新公告：子公司通过GLP定期检查并获得《药物GLP认证证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2478179778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478179778?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:09","pubTimestamp":1730106593,"startTime":"0","endTime":"0","summary":"白云山公告称，其全资子公司广州医药研究总院有限公司（广药总院）顺利通过国家药品监督管理局的GLP定期认证检查，并获得了《药物GLP认证证书》。广药总院为公司主要研发平台之一，具备了9项药物非临床安全性评价项目认证资质能力，有利于承接自主研发项目和对外承接药物非临床安全性评价业务，提升公司药物创新研发综合实力。该证书有效期至2029年10月14日。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800023067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0196","BK0028","BK1606","600332","BK0070","BK1197","BK0096","00874","BK1521","BK0097","BK0239","BK1191","BK0012","BK1515","BK0183"],"gpt_icon":0},{"id":"2478111213","title":"港股指数小幅高开 恒指微升0.01% 信义光能(00968)涨2.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478111213","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478111213?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:26","pubTimestamp":1730078760,"startTime":"0","endTime":"0","summary":"金吾财讯 | 市场观望情绪浓厚，港股指数小幅高开，恒指微升0.01%，国企指数升0.09%，恒生科技指数涨0.57%。信义光能涨2.38%，中国宏桥涨2.09%，海底捞涨1.94%，吉利汽车涨1.6%。2024年前9个月，公司净利录得104.28亿元，同比增长108.78%；营收录得1422.54亿元，同比增长19.04%，基本每股收益1.23元，同比增长108.47%。投资者关注企业业绩消息及观望美国总统大选结果，大市短期维持上落局面，指数在20,200至21,200点水平徘徊。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/OGZiMjA2ODIyZGU2MjU4NjM4OTk5NzExMDU3ODE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/OGZiMjA2ODIyZGU2MjU4NjM4OTk5NzExMDU3ODE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c683a361061086282b22c2b5253306e2","isJumpTheme":false,"source_url":"1946569","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1197","BK1554","HSImain","02833","IE00BZ08YS42.EUR","00874","HSCEI","BK1589","513600","HHImain","BK1191","MCHmain","YANG","LU1983299162.USD","BK1515","HSI","IE00BZ08YR35.GBP","00968","MHImain","IE00BZ08YT58.USD","BK1606","HSTECH","00175","BK1521","BK1169"],"gpt_icon":1},{"id":"2478154832","title":"《业绩》白云山(00874.HK)首三季赚31.59亿人民币  倒退16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478154832","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478154832?lang=zh_cn&edition=full","pubTime":"2024-10-27 19:23","pubTimestamp":1730028180,"startTime":"0","endTime":"0","summary":"白云山公布9月止首三季度业绩，按中国会计准则，实现营业收入590.6亿人民币(下同)，按年增加1.5%。归属股东净利润31.59亿元，倒退16.7%，主要受宏观经济波动、市场竞争等影响，下属子公司销售收入减少；每股收益1.943元。(港股报价延迟最少十五分钟。沽空资料截至 2024-10-25 16:25。)过往派息公布日期派息事项派息内容2024/08/30中期业绩普通股息：人民币 0.4 2024/04/26第一季业绩无派息2024/03/15末期业绩普通股息：人民币 0.749 2023/10/30第三季业绩无派息AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190128164618458_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190128164618458_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1391345/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0096","BK0239","BK0175","600332","BK1521","BK1606","00874","BK0097","BK1515","BK0183","BK1191","BK0070","BK1197","BK0028","BK0188","BK0196","BK0012"],"gpt_icon":0},{"id":"2478935996","title":"白云山前三季度净利31.59亿元，同比下降16.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478935996","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478935996?lang=zh_cn&edition=full","pubTime":"2024-10-25 21:50","pubTimestamp":1729864200,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 丁宁）10月25日晚间，白云山(600332)发布三季报显示，公司前三季度实现营业收入590.6亿元，同比增长1.5%；对应实现的归属净利润31.59亿元，同比下降16.68%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-10-25/doc-inctuumm8598714.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-10-25/doc-inctuumm8598714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","BK1197","BK0175","BK0028","BK1191","BK0097","BK0096","BK1521","BK0012","BK0183","BK0188","BK1515","BK0239","BK0196","600332","BK1606","00874"],"gpt_icon":0},{"id":"2478988251","title":"白云山(600332.SH)发前三季业绩，净利润31.59亿元，同比减少16.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478988251","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478988251?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:09","pubTimestamp":1729854583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)发布2024年前三季度报告，报告期内公司实现营业收入590.60亿元，同比增长1.50%;归属于上市公司股东的净利润31.59亿元，同比减少16.68%;归属于上市公司股东扣除非经常性损益净利润28.56亿元，同比减少16.95%;基本每股收益1.943元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600332","00874"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gybys.com.cn","stockEarnings":[{"period":"1week","weight":-0.0212},{"period":"1month","weight":-0.1196},{"period":"3month","weight":-0.0557},{"period":"6month","weight":-0.0851},{"period":"1year","weight":-0.0677},{"period":"ytd","weight":-0.0977}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0954},{"period":"3month","weight":0.2355},{"period":"6month","weight":0.1231},{"period":"1year","weight":0.1644},{"period":"ytd","weight":0.2065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州白云山医药集团股份有限公司从事制药和保健行业。该公司的业务分部包括：大南药分部、大健康分部、大商业分部和大医疗分部。大南药分部从事研究、开发、制造和销售中西成药、化学原料药、天然药物、生物医药和化学原料药中间体业务。大健康分部从事研究、开发、制造和销售饮料、食品、保健品等产品。大商业分部从事批发、零售和进出口西药、中药和医疗器械业务。大医疗分部从事医疗服务、中医养生、现代养老以及医疗器械产业。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.011967},{"month":2,"riseRate":0.692308,"avgChangeRate":0.062033},{"month":3,"riseRate":0.62963,"avgChangeRate":0.059521},{"month":4,"riseRate":0.666667,"avgChangeRate":0.087941},{"month":5,"riseRate":0.555556,"avgChangeRate":0.049452},{"month":6,"riseRate":0.481481,"avgChangeRate":0.021437},{"month":7,"riseRate":0.407407,"avgChangeRate":-0.018239},{"month":8,"riseRate":0.37037,"avgChangeRate":-0.039061},{"month":9,"riseRate":0.407407,"avgChangeRate":-0.011257},{"month":10,"riseRate":0.407407,"avgChangeRate":0.002825},{"month":11,"riseRate":0.464286,"avgChangeRate":0.009329},{"month":12,"riseRate":0.538462,"avgChangeRate":0.027564}],"exchange":"SEHK","name":"白云山","nameEN":"BAIYUNSHAN PH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,00874,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}